FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Related Topics >> Ception Therapeutics

Ception Therapeutics - Top 20 VC deals of 2007

Tools

Company: Ception Therapeutics
Based: Malvern, PA
Amount: $77.7M
Round: Third
Investors: Aperture Venture Partners, Essex Woodlands Health Ventures, Greenlight Capital, Individuals, Investor Growth Capital, Lumira Capital Corporation, New Science Ventures, Undisclosed Investor

Scoop: Ception's pipeline includes a late-stage biologic agent (Anti-IL5 MAb) in clinical development for eosinophilic esophagitis and other inflammatory conditions. The company is also working on an oral Anti-TNF drug, an anti-infective program and a novel anti-thrombotic program.

More News:
Ception adds $14.7M to big third round. Report
Ception Therapeutics pockets $63M in third round. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Ception Therapeutics  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.